Neurocrine Biosciences Inc vs Carparts.Com Inc — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while Carparts.Com Inc trades at $6.41 (market cap $52.07M). The key difference: Neurocrine Biosciences Inc is far larger — about 321.9× Carparts.Com Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PRTS | |
|---|---|---|
Market Cap | $16.76B | $52.07M |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $11.40 |
52-Week Low | $123.10 | $3.88 |
Enterprise Value | $16.78B | $67.05M |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
CarParts.com (PRTS) is trading at $6.75, up 16.68% with bullish technical signals and strong analyst support. The company shows improving operational performance with three consecutive quarterly earnings beats, though it remains unprofitable with negative net margins. Recent developments include a 10:1 reverse stock split completed in May 2026 and a new $25 million credit facility, providing financial flexibility amid challenging market conditions.
The outlook remains cautiously optimistic with 60% analyst buy ratings supporting recovery potential, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investors should focus on the company's ability to leverage proprietary data advantages while monitoring progress toward profitability in the competitive auto parts e-commerce sector.
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →